Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. A live, listen-only webcast will be available on the Company's website at www.

Geron to Announce Third Quarter Financial Results on November 5, 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology. The article entitled, “Imetelstat Achieves Meaningful and Durable Transfusion Independence in High-Transfusion Burden Patients with Lower Risk Myelodysplastic Syndromes Patients in a Phase 2 Study,” is available online. The publication includes data from all 57 patients

Geron Announces Publication of IMerge Phase 2 Data in Journal of Clinical Oncology

Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron (GERN) Expected to Beat Earnings Estimates: Should You Buy?

Hercules Capital

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive financial resources to support the imetelstat development program, as well as working capital and general corporate purposes. “This debt financing strengthens o

Geron Secures Loan Facility for Up to $75 Million

Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Geron (GERN) Looks Good: Stock Adds 6.5% in Session

Geron Corporation (GERN) CEO John Scarlett Presents at H.C. Wainwright Global Investment Conference Transcript

Geron Corp (GERN) CEO John Scarlett on Q2 2020 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020.

Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

Geron to Present at the BTIG Virtual Biotechnology Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors.

Geron to Announce Second Quarter Financial Results on August 6, 2020

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Geron (GERN) Report Negative Q2 Earnings? What You Should Know

Geron has been struggling lately, but the selling pressure may be coming to an end soon

Geron Sees Hammer Chart Pattern: Time to Buy?

Is  (GERN) Outperforming Other Medical Stocks This Year?

Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?

MENLO PARK, Calif., July  01, 2020  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company’s application for orphan drug designation of its first-in-class telomerase inhibitor, imetelstat, as a potential treatment for myelodysplastic syndromes (MDS). The Company expects that the European Commission, based on this positive opinion of the COMP, will formally grant the orphan drug designation for the European Union (EU) by the end of July. Imetelstat has already been granted orphan drug designation by the United States Food and Drug Administration as a potential treatment for MDS.

Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes

As of late, it has definitely been a great time to be an investor in Geron.

Geron's Shares March Higher, Can It Continue?

Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.

Implied Volatility Surging for Geron Corporation (GERN) Stock Options

MENLO PARK, Calif., June  12, 2020  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, are now available on Geron’s website as well as to participants of the Virtual Edition of the 25th Annual EHA Annual Congress.   

Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress

Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Geron

Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Geron Corporation (GERN) Stock Stands Out in a Strong Industry

Alexco Resource

Co-Diagnostics

Top Ranked Momentum Stocks to Buy for June 5th

Top Ranked Momentum Stocks to Buy for June 5th 2020

Geron Corp (GERN) CEO John Scarlett on Q1 2020 Results - Earnings Call Transcript

Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates

MENLO PARK, Calif., May  28, 2020  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss the recently announced planned Phase 3 clinical trial in refractory MF, as well as an update on the ongoing IMerge Phase 3 clinical trial in lower risk MDS and first quarter financial results.

Geron Corporation Reports First Quarter 2020 Financial Results

Shares of Geron Corp. GERN, +3.70% plunged 26% in premarket trading Friday, after the biopharmaceutical company's large public offering of stock priced at a 34% discount.

Geron's stock tumbles after large share offering prices at 34% discount

MENLO PARK, Calif., May  21, 2020  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in MF patients who are refractory to treatment with a janus kinase (JAK) inhibitor, including trial design and expected timelines for trial start and future data readouts. Geron also provided an update on its ongoing IMerge Phase 3 clinical trial in lower risk MDS and reported revised fiscal year 2020 operating expense guidance.

News for Geron Stock (GERN)